Novartis management replaced

Novartis management replaced

TOKYO, Japan - Dirk Kosche, new president of Novartis Pharma K.K., speaks during a press conference in Tokyo on April 3, 2014. The Japanese sales arm of Swiss pharmaceutical giant Novartis announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.

  • Product Code
  • ILEA001197407
  • Registered date
  • 2014/4/03 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2014 Kyodo News
  • Media size
  • 2582 × 3871 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 961.90(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Novartis management replaced

    Novartis management replaced

    TOKYO, Japan - David Epstein (L), president of Swiss pharmaceutical giant Novartis speaks during a press conference in Tokyo on April 3, 2014. The Japanese sales arm of the company, Novartis Pharma K.K., announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors. At right is new Novartis Pharma K.K. President Dirk Kosche.
      Novartis management replaced

      Novartis management replaced

      TOKYO, Japan - David Epstein, president of Swiss pharmaceutical giant Novartis holds a press conference in Tokyo on April 3, 2014. The Japanese sales arm of the company, Novartis Pharma K.K., announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.
        Takeda chief apologizes over data misuse in drug ad

        Takeda chief apologizes over data misuse in drug ad

        TOKYO, Japan - Takeda Pharmaceutical Co. President Yasuchika Hasegawa apologizes during a press conference in Tokyo on March 3, 2014, over an advertisement for the company's blood pressure-lowering drug that made it appear the product is more powerful in suppressing diseases than other medicines.
          Takeda chief apologizes over data misuse in drug ad

          Takeda chief apologizes over data misuse in drug ad

          TOKYO, Japan - Takeda Pharmaceutical Co. President Yasuchika Hasegawa apologizes during a press conference in Tokyo on March 3, 2014, over an advertisement for the company's blood pressure-lowering drug that made it appear the product is more powerful in suppressing diseases than other medicines.
            Novartis scandal

            Novartis scandal

            TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks in a press conference in Tokyo on Oct. 3, 2013. At right is Yoshiyasu Ninomiya, president of Novartis Pharma K.K., a Japanese unit of Novartis AG. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.
              Novartis scandal

              Novartis scandal

              TOKYO, Japan - David Epstein (C), division head at Novartis AG, the Swiss-based pharmaceutical giant, and Yoshiyasu Ninomiya (R), president of Novartis Pharma K.K., a Japanese unit of Novartis AG, bow in apology during a press conference in Tokyo on Oct. 3, 2013. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.
                Novartis division head Epstein

                Novartis division head Epstein

                TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, holds talks with Japanese Health, Labor and Welfare Minister Norihisa Tamura (R) at the ministry in Tokyo on Sept. 26, 2013. Tamura summoned Epstein and sharply criticized the firm for triggering a scandal involving Novartis Pharma K.K., the Japanese subsidiary of Novartis AG. The unit allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.
                  Novartis Pharma

                  Novartis Pharma

                  TOKYO, Japan - Yoshiyasu Ninomiya, president of Novartis Pharma K.K., attends a press conference in Tokyo on July 29, 2013. Novartis Pharma, a Japanese unit of Swiss drug company Novartis AG, said it has found no evidence a former employee manipulated or altered clinical research data for the drugmaker's Diovan blood pressure lowering drug.
                    Data altered in Japanese research for Novartis blood pressure drug

                    Data altered in Japanese research for Novartis blood pressure drug

                    TOKYO, Japan - Toshikazu Yoshikawa (2nd from L), president of the Kyoto Prefectural University of Medicine, and Shinji Fushiki (L), the university窶冱 vice president, bow toward the end of a press conference in Kyoto on July 11, 2013. Yoshikawa apologized as the university found that data employed in a clinical study on Novartis Pharama K.K.'s blockbuster blood pressure lowering drug Diovan were manipulated.
                      Japan doctor offers medical relief abroad

                      Japan doctor offers medical relief abroad

                      TOKYO, Japan - Nobuko Kurosaki, president of the Japanese arm of Doctors without Borders, speaks on May 21, 2013 at the entity's office in Tokyo's Shinjuku Ward. Kurosaki, who assumed her current position in March 2010, has offered humanitarian medical aid as a volunteer surgeon on a total of 11 missions to such countries as Sri Lanka, Somalia and Jordan since 2001. Most recently she was in Syria for about a month from mid-April.